Pharmaceutical

Sanofi Strengthens STAT6 Pipeline with Nurix Sanofi Nurix Sanofi expands its collaboration with Nurix by licensing NX-3911, a potent STAT6 degrader targeting inflammatory diseases. The deal includes $15M upfront and up to $465M in milestones, with Nurix retaining U.S. co-development rights.
Regeneron Secures $2B Deal for Hansoh’s Obesity Drug Rivaling Zepbound Regeneron Hansoh Pharma Regeneron signs a $2B deal with Hansoh Pharma for HS-20094, a GLP-1/GIP receptor agonist aimed at rivaling Eli Lilly’s Zepbound in the obesity market. The deal boosts Regeneron's obesity pipeline with late-stage drug access and new combo therapy potential.
Bristol Myers Joins BioNTech in $11B Bispecific Pact BMS BioNTech Bristol Myers Squibb partners with BioNTech in an $11B deal to co-develop the PD-L1xVEGF-A bispecific BNT327, strengthening its immuno-oncology portfolio amid rising competition from Merck and Pfizer.
ASCO 2025: 14 Chinese ADC Therapies Showcase Strong Efficacy Across Multiple Tumors ASCO Market Trend ADC At ASCO 2025, 14 Chinese ADC therapies demonstrated impressive efficacy and safety across various cancers, including breast, lung, gastric, and urothelial, signaling strong global potential for domestically developed treatments.
IBI-363 Shines at ASCO 2025: Innovent’s Breakthrough Immunotherapy Shows Game-Changing Results ASCO Market Trend Innoventbio Discover how Innovent's IBI-363 made a groundbreaking impact at ASCO 2025 with impressive efficacy in NSCLC, melanoma, and colorectal cancer. A potential game-changer in next-gen immunotherapy.
Intellia’s Gene Therapy Nex-z Faces Safety Concern but Analysts Remain Positive Intellia Therapeutics Intellia Therapeutics' gene therapy nex-z saw a stock dip after a grade 4 liver enzyme elevation in a phase 3 trial, but analysts remain confident in its safety and clinical potential for treating ATTR and hereditary angioedema.
FDA Rejects Elamipretide Despite Support, Stealth Biotherapeutics Plans Resubmission FDA Stealth Biotherapeutics Stealth Biotherapeutics faces FDA rejection for elamipretide, a treatment for Barth syndrome, despite a favorable advisory vote. The company plans a resubmission amid layoffs and calls for swift regulatory action.
Merck and Daiichi Sankyo Withdraw Lung Cancer Drug Filing After Trial Misses Survival Goal Biotech Merck Daiichi Sankyo Merck and Daiichi Sankyo have withdrawn their FDA application for patritumab deruxtecan after a Phase III trial failed to show significant overall survival benefits in EGFR-mutated NSCLC patients, citing regulatory discussions.
ASCO 2025 Colorectal Cancer Highlights: Plenary & Oral Sessions, Breakthrough Treatments & Studies ASCO Market Trend Cancer Discover the latest breakthroughs in colorectal cancer at ASCO 2025, featuring key plenary and oral presentations on innovative treatments like ATOMIC, BREAKWATER, ANCHOR, and KRAS G12C inhibitors. Stay ahead in oncology research.
Trump's Pharma Tariffs & Pricing Reforms: S&P Warns of Generic Sector Risks Trump Market Trend S&P Global reports that major pharma companies can withstand Trump’s proposed drug tariffs and MFN pricing, but warns that generic manufacturers may face serious risks from cost pressures and supply chain disruptions.